H.C. Wainwright & Co., LLC’s Post

The way to win at healthcare investing is knowing the best companies BEFORE they are public. Thanks, LifeSci, for blazing the trail.

FTC Greenlights Amgen's $27.8 Billion Acquisition of Horizon Therapeutics 🚀 FTC Allows Amgen to Move Forward with $27.8 Billion Horizon Therapeutics Acquisition Read More: https://cutt.ly/Mwlgt6sS #Amgen #HorizonTherapeutics #FTCApproval #PharmaMergers #HealthcareIndustry #BusinessNews

On Tuesday we announced our first quarter 2024 financial results. On the earnings call, CEO Todd Davis, and members of the Ligand senior management team, highlighted our positive momentum during the first quarter, the significant progress of our commercial and development stage portfolio including our recent #royaltyfinancing agreement with Agenus and the launch of Pelthos Therapeutics, and the key growth drivers for the remainder of the year. View our earnings release here: https://bit.ly/4acV1D5

Axsome Therapeutics ( $AXSM ) ACTIVELY RESPONDS TO THE MARKET with average analyst rating of BUY from 14 analysts: Axsome Therapeutics employs about 502 people. The company is managed by 21 executives with a total tenure of roughly 94 years, averaging almost 4.0 years of service per executive, having 23.9 employees per reported executive. Axsome Therapeutics reports 45.94 m gross profit. Axsome Therapeutics is selling for under 92.81. That is -0.7 percent down. Today highest was 93.88. https://lnkd.in/gde_X3yK #hotstocks #investing #trading

If your team is using #Slack for internal IT Helpdesk Support and that experience could be improved, I have two suggestions: 1) Sign up for this Foqal webinar; and 2) contact me!!!

Indeed, it was an interesting discussion about the #ATMP translation into commercialization and accessibility challenges. The comparability and robustness issues & with quality and safety in mind were mentioned as well. It is not always easy to have all the required expertise in house. Therefore the collaborative approach could be a good solution for the #ATMP developers.

Do you want an update on what's been happening at Argenica Therapeutics? This morning, we released our most recent Investor Presentation, providing an update on our Phase 2 Clinical Trial. Read the full presentation here➡️ https://bit.ly/4f4NZ70 #clinicaltrial #investorupdate #AGN #ASX #stroke #strokeawareness

Last week, Argenica Therapeutics lodged our Appendix 4C Quarterly Cashflow Report for the 12-month period ended 30 June 2024. One key highlight from the report was the progress made in our Phase 2 Clinical Trial. Here is an overview of the highlight Access the full report here ➡️ https://bit.ly/4ftygiq #ASX #AGN #investorupdate #stroke #clinicaltrial

The interim report for the third quarter is now available! Stayble Therapeutics has published its interim report for the third quarter of 2023. Comment from our CEO, Andreas Gerward: “We at Stayble aim for every shareholder to clearly understand the differences between our two different indications. From now on, we will carefully analyze the data from the phase 2b study. We plan to update the market with more detailed information on all the data and explain why our belief in the potential of the herniated disc project still remains.” Explore the full report by following the link: https://lnkd.in/emAFbjw5  

Fascinating keynote panel by Miguel Forte from Kiji Therapeutics, Tara Sadeghi from Cellenkos, Inc. Seth Ettenberg from BlueRock Therapeutics and Katy Newton from Achilles Therapeutics plc talking about key considerations for ensuring commercial sustainability! #adtherapies24